TriangleCPX-351 + Gemtuzumab Ozogamicin (NCT05558124)
CPX-351 + Gemtuzumab Ozogamicin trial for Newly Diagnosed Acute Myeloid Leukemia (NCT05558124). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with newly diagnosed acute myeloid leukemia.
The idea: combine CPX-351, also called Vyxeos, a fixed dose of daunorubicin and cytarabine chemotherapy, with gemtuzumab ozogamicin, an antibody that carries a toxin to leukemia cells. Different doses and schedules of gemtuzumab are tested.
The study looks at safety, the maximum tolerated dose, and the recommended dose for phase 2.
This phase 1 study plans 18 patients. At Moffitt Cancer Center in Tampa, Onyee Chan leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.